Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIEZO-101 in Healthy Adult Females for Skin Rejuvenation
NCT07671027Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, open-label trial of PIEZO-101 in Skin aging (2 arms). Primary endpoint: Safety and tolerability of intradermal delivery of PIEZO-101 followed by Piezopen EP up to 3 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
PIEZO-101
03
Conditions
Skin aging
Beyond the preview
Go deeper on NCT07671027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671027.